Objective: To describe the characteristics of patients suffering from secondary immunodeficiencies (SID) associated with hematological malignancies (HM), who started immunoglobulin replacement therapy (IgRT), physicians' expectations regarding IgRT, and IgRT modalities.
| INTRODUC TI ON
Secondary immunodeficiencies (SID) are acquired through various factors affecting host's immune system which was originally normal. Due to the various origins and causative diseases, SID manifestations are heterogeneous. However, these patients share common features. The main immune disturbance includes neutropenia, humoral or cellular immune defect, and hypogammaglobulinemia (HG). SID is frequently encountered in individuals suffering from hematological malignancies (HM) and can be caused by the disease itself or its management, that is, high-dose chemotherapy, fludarabine, rituximab, stem-cell transplantation, or radiotherapy. 1, 2 HM-associated SID are markedly frequent in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and also non-Hodgkin lymphoma (NHL). Given the frequency of HM, HM-associated SID is of paramount importance. MM-related SID combines B-cell dysfunction resulting in HG, and T-cell, dendritic cell, and natural killer cell alterations. CLL alters the cell-mediated immunity, complement, neutrophil functions, and antibody production. 3 NHL consists of more than 20 different lymphoproliferative disorders and is also associated with SID, although specific prevalence of HG and related mechanism are less documented. Immunodeficiency can also be secondary to management of HM. MM therapy includes chemotherapeutic agents and immunosuppressants which further impair the immune system. CLL treatment, such as chemotherapy, further deteriorates the host immune status. 3 Treatment of NHL has been associated with HG. 4, 5 Chemotherapies with alkylating agents or purine analogues, immunotherapy (anti-CD20 and anti-CD52 monoclonal antibodies), or the combination of both is associated with HG. 6 HM-associated SID exposes the patient to an increased risk of infections which are acknowledged as the main causes of morbidity and mortality in MM and CLL patients. to respond to pneumococcal immunization. 7 The same recommendation is made for CLL patients with HG and recurrent bacterial infections despite the use of prophylactic antibiotics. HG after allogeneic hematopoietic stem-cell transplantation is also to be treated with the same IVIg dose to maintain serum IgG trough levels above 5 g/L. 7 The subcutaneous route (SCIg) may also be used in these indications, with a cumulative monthly maintenance dose of 0.4-0.8 g/ kg once stable IgG levels have been reached. 8 There are no specific guidelines regarding the management of patients presenting with other B-cell malignancies and SID. Use of modern therapies such as anti-CD20 monoclonal antibodies is increasing and may raise specific concerns. 9 Hence, it would be interesting to know the current mode of use of IgRT in SID associated with lymphoid malignancies. Thus, the objective of our study was to describe in real-life conditions the indications and modalities for
IgRT implementation in patients suffering from HM-associated SID in France.
| ME THODS

| Study design and objectives
This study had an observational, multicenter, prospective design.
The study was open for enrollment in different investigation centers for a period of 12 months from the date of study initiation.
Consecutive adult patients with HM-associated SID who were newly prescribed IgRT, regardless of route (IVIg or SCIg), or place of administration (hospital or home), were included in the study.
Patients having received IgRT at any time within the last 12 months prior to the visit could not enter the study. The study aimed at describing HM history, clinical status, and comorbidities of HMassociated SID patients starting IgRT, physicians' expectations regarding IgRT, and modalities of IgRT. 
| Data collected
| Statistics
Continuous variables were summarized by the number of observations, mean and standard deviation, extreme values, and median. Statistical evaluations were performed using the software package SAS release 9.4 (SAS Institute Inc., Cary, NC, USA).
| Ethics
The 
| RE SULTS
| Patient disposition
The study enrolled 238 patients. Seven patients were excluded from the analysis for one or more reasons: age under 18 years (n = 1), no hematological malignancy (n = 1), no prescription of IgRT (n = 2), patient's refusal to participate (n = 2), wrongly included patient (n = 2), patient affected with monoclonal gammopathy of undetermined significance (MGUS, n = 3), and Ig dose not compatible with IgRT for SID (n = 2). Consequently, 231 patients from 29 centers formed the full analysis set.
| Demography
Patients had a mean age of 66. On the contrary, patients with CLL and aNHL were most likely not on therapy at that time (Table 1) .
| Hematological malignancies
| Comorbidities
Comorbidities were autoimmune cytopenia in 18 (8.2%) patients, rheumatoid arthritis in 3 patients, Sjögren's syndrome in 3 patients, idiopathic thrombocytopenia in one patient, cutaneous erythematous disseminated lupus in one patient, and antiphospholipid syndrome in one patient. Renal insufficiency was present in 35 (16.6%) patients; 27 (12.3%) patients were suffering from diabetes mellitus.
| History of infections over the 12 months before enrollment
Patients experienced a mean of 2.23 ± 1.57 (median = 2) infections within the 12 months before enrollment with higher rates observed in iNHL; 1.89 ± 1.50 episodes required antibiotics; 0.48 ± 0.76 were treated with intravenous antibiotics; and 0.60 ± 0.87 infections led to hospitalization. Seventy-nine patients (36.1%) had at least one severe infection (WHO grade > 2).
Infection was the cause of at least one hospitalization within the 12 months before enrollment in 90 patients (Table 2) . Eleven (5.0%) patients have received antibioprophylaxis (apart from valaciclovir and trimethoprim/sulfamethoxazole). 
| Serum Ig levels
| Immunoglobulin replacement therapy
Half of patients (N = 106) started IgRT by intravenous route, while the other half (N = 113) used the subcutaneous route. There were no differences between IVIg and SCIg patients except on ECOG-PS score which was lower in IVIg patients (P < .0001). No difference was found on patients' renal function at enrollment. All first IVIg infusions and almost all first SCIg infusions (109 of 113 patients)
were performed at hospital. Further IVIg infusions were planned to be pursued at hospital (105 of 106 patients 99.1%), whereas further SCIg were expected to be self-administered at home (110 of 113 patients; 97.4%). IVIg were planned to be administered once a month, whereas SCIg were expected to be performed weekly at a fourfold lesser dose (median prescribed dose 99 mg/kg for weekly SCIg vs 385 mg/kg for monthly IVIg).
| Physicians' expectations
When prescribing IgRT, physicians declared their expectations were high or very high to prevent both severe (87.7%) and moderate infections (82.9%), and to decrease antibiotic consumption (82.6%) and hospitalization rates (74.2%). Interestingly, physicians also anticipated improvement of quality of life (74.7%) and survival (56.5%) ( Figure 1 ).
| D ISCUSS I ON
The study aimed at describing patients with HM for whom physicians decided to start IgRT in real practice. CLL and MM were the two most common HM for which IgRT was introduced. Such figures are in accordance with recent observations of Blot et al who studied 389 patients with secondary HG. 10 They found that HM was the main etiology for secondary HG with MM being the most prevalent form, followed by lymphoma and CLL. Our results also showed that other HM, such as indolent or aggressive NHL, are emerging as 
TA B L E 2 History of infections within 12 mo before enrollment (mean ± SD or number [%])
F I G U R E 1 Physicians' expectations when prescribing IgRT. Red bars = none; yellow bars = moderate; light green bars = important; dark green bars = very important. From the overall patient population (N = 219), data were missing for the following response: secondary prevention of moderate infections (n = 8), secondary prevention of severe infections (n = 8), survival improvement (n = 3), quality-of-life improvement (n = 2), decrease in the number of hospital admissions (n = 6), and decrease in antibiotic consumption (n = 1)
| HM-associated SID
HM can intrinsically lead to the alteration of immune system. CLL is characterized by a decreased proliferation of B cells, an impaired production of Ig, alteration of interactions between tumor cells and normal B cells, neutropenia, and lack of complement components.
As high as 85% of patients suffering from CLL are diagnosed with a HG 10,12,13 impacting the 3 classes (IgG, IgA, and IgM), frequently combined with decreased cellular immunity. 13 Infections are the leading cause of death of CLL patients 13, 14 accounting for more than 50% of deaths. Decreased polyclonal Ig is frequently encountered in patients with MM which is characterized by a proliferation of monoclonal plasma cells. 15 Infections are the cause of death of more than one-third of patients with myeloma. 16 Deficiency of the cellular immunity increases the risk of viral infections. 17 In lymphoma, B-and/ or T-cell lymphopenia can be linked to tumor proliferation or to immunochemotherapy. Lymphopenia increases the risk of opportunistic infections.
In all cases, SID can be induced or aggravated by the treatments given for HM or comorbidities as corticosteroids for autoimmune cytopenia. Rituximab had increased physician's armamentarium for the treatment of HM, although it is relatively clear that maintenance rituximab therapy alone or in combination with other drugs is a risk factor of infection and HG. 4, 5, 18 Our study provides data on MM and CLL, two well-known hematological malignancies, but also on indolent non-Hodgkin B-cell lymphoma.
| Decision-making process
Serum Ig levels were monitored before starting IgRT in the majority but not in all patients with a median value of 4.10 g/L. In the SIGNS study, serum Ig level was known in 32 newly patients at IgRT initiation with a lower median value of 3.6 g/L). 11 IgRT was prescribed in 24 patients without serum Ig level assessment. Serum Ig was less than 5 g/L in 68.7% of patients, a limit that has been proposed by some authors. 10 
| Route of IgRT
Half of patients started IgRT via the subcutaneous route independently of the underlying HM. The physician's decision is supported by different studies showing the similar performance of SCIg in managing HG and infection risk as compared to IVIg in SID patients. 19, 26 This decision seemed to be related to the patient's and/or physician's wish to pursue home-based IgRT. Patients with lower ECOG-PS score were more prone to be followed up at hospital and to receive hospital-based IVIg. No other difference was found between patients regarding the route of administration. By contrast, Reiser et al observed that IVIg was the most used route of administration (95.4%) with SCIg more likely administered to younger patients and at a higher dose (199 vs 343 mg/kg per 4 weeks, respectively).
11
These differences could be explained by local practices.
| Physicians' expectations
Were physicians' expectations in line with evidence-based medicine data? The main expectations were the reduction in severe but also moderate infections and, as a result, the decrease in antibiotic consumption and hospitalizations. Several studies have demonstrated that IgRT decreases bacterial infection rates in CLL patients. The
Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia showed that patients receiving 0.4 g/kg IVIg every 3 weeks had less bacterial infections compared to those receiving placebo. 27 In a crossover study on 12 patients with CLL or NHL presenting with HG or a history of recurrent infections, IVIg every 3 weeks for 1 year reduced the number of serious bacterial infections. 28 Further studies confirmed these results. [29] [30] [31] In plateauphase MM patients, a placebo-controlled, randomized, double-blind trial showed that monthly IVIg infusion (0.4 g/kg) for 1 year prevented episodes of septicemia or pneumonia. 32 A monocenter retrospective analysis on 61 patients affected with HG secondary to various B-cell lymphoproliferative disorders showed a reduction in the annual rate of infectious episodes with SCIg treatment compared to the period before IgRT, from 0.46 to 0.11 episodes per patient-year. Consequently, antibiotic cycles were also reduced after SCIg implementation from 2.35 to 1.43 cycles per patient-year. 19 A recent postmarketing study on a limited number of patients (n = 10)
showed that the average incidence of infections decreased from 9.6
(extrapolated from 3-month data) to 1.4 infections per patient per year. 21 Finally, a meta-analysis estimated a risk ratio (RR) of 0.45 (95% CI 0.27-0.75) for major infections with IVIg in HM-associated HG. 33 In the group of newly initiated IgRT of the SIGNS study, the 82% overall infection rate dropped to 35% at 6 months and 21%
1 year after initiation of treatment.
Physicians expected also indirect benefits on patients' survival. to demonstrate any benefit on survival. 33 In a systematic review and meta-analysis of 30 studies involving 4223 patients undergoing bone marrow transplantation (mostly for AL), polyvalent IVIg had no impact on mortality compared to control. 35 Therefore, current available data do not support survival improvement through IgRT, suggesting that physician's expectations in this regard were mainly based on circumstantial evidence, that is, reduction in the risk of infection and morbidity. It should be highlighted that studies involved in the two meta-analyses 33,35 estimated one-year or two-year survival rates, and this may explain that no effect on mortality was doc-
umented. 11 These studies demonstrated at least that no benefit on short-term mortality could be expected.
| Evolution of recommendations
Benefit of IgRT in MM and CLL patients to manage the risk of infections is commonly acknowledged by current recommendations.
Several guidelines and experts, however, consider but do not systematically recommend IgRT in HG and infectious risk management. 2,14,23 Evolution of guidelines is expected. Current EMA guidelines for IgRT implementation are still based on total Ig levels. 7, 8 Experts have suggested that in addition to history of infection and HG, immunization responses in CLL patients could be of value to stratify infectious risk and select patients for IgRT. 14 The Wildbad Kreuth advisory group acknowledged the consideration of documented specific antibody production failure along with recurrent infections and HG in patients HM-related SID including CLL. However, they recommended further research to assess patient suitability for
IgRT based on these conditions. 36 
| LIMITATI ON S OF THE S TUDY
We acknowledge our study has some limitations inherent to its observational nature. Although a large number of French centers in charge of HM patients have been included in the study, they could not be deemed representative of all French centers. Indeed, centers were not randomly selected. In addition, as recruitment was competitive, our results were driven by the most active centers.
One hundred and thirty-five patients were recruited by 5 centers, and 96 patients were recruited by the remaining 24 centers. We also did not collect data on HM patients who did not start IgRT, and
we were then unable to compare their characteristics to better understand the decision-making process. We also did not collect data on vaccinations which are recommended at least in CLL, MM, and Waldenström patients 1,2 and could ever contribute to the decision to start IgRT. According to the current EMA guidelines, IVIg is indicated in MM patient with HG and recurrent infections in whom response to pneumococcal immunization has failed. 7 Astonishingly, this condition is no longer retained in recent EMA recommendations for SCIg. 
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